QurAlis
MA - CambridgeBiotechnology
Focus: QurAlis is a public-stage biotech company focused on discovering and developing small molecule and antisense oligonucleotide (ASO) therapeutics for amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. The company operates as a specialized neurology-focused biotech with a concentrated pipeline targeting an unmet medical need in a rare disease indication.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About QurAlis
AI assessmentNot HiringNo open roles listed right now. Follow QurAlis to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
7 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
QRL-101
Healthy VolunteersClinical Trials (1)
NCT06532396A Study Evaluating Multiple Ascending Doses of QRL-101 in Healthy Participants
Phase 1Help build intelligence for QurAlis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.